Core Viewpoint - Inspire Medical Systems, Inc. is facing a federal securities class action due to allegations of misleading statements regarding the launch and demand for its Inspire V device, with a deadline for investors to seek lead plaintiff status set for January 5, 2026 [1][3]. Group 1: Allegations and Legal Action - The complaint claims that Inspire Medical and its executives violated federal securities laws by making false or misleading statements about the market demand for the Inspire V device and the company's readiness for its launch [3]. - The law firm Faruqi & Faruqi is investigating potential claims against Inspire Medical and encourages anyone with relevant information to come forward [7]. Group 2: Launch Issues and Financial Impact - On August 4, 2025, Inspire Medical announced significant delays in the launch of the Inspire V device, citing incomplete training and onboarding at treatment centers as major factors [4]. - The company also faced billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, 2025, preventing implanting centers from billing for procedures [4]. - Inspire reported weak demand and excess inventory for the Inspire V, leading to a drastic cut in its 2025 earnings guidance by over 80% [5]. - Following these announcements, Inspire's stock price plummeted by more than 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [5].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Summary by Relevant Sections Lawsuit Details - The lawsuit is pending in the U.S. District Court for the District of Minnesota and targets investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2][3]. - The Lead Plaintiff Deadline is set for January 5, 2026, urging affected investors to contact legal representatives [3]. Allegations of Misleading Information - Inspire Medical allegedly assured investors of its "operational readiness" for the Inspire V launch, claiming it was ready for a full commercial rollout, which the lawsuit argues concealed significant operational failures [3][4]. - The undisclosed operational issues included: - **Medicare & Billing Readiness**: Necessary software updates for Medicare claims processing were not effective until July 1, 2025, preventing implanting centers from billing for procedures, which stalled early adoption and revenue generation [4]. - **Excess Inventory**: A significant surplus of the older Inspire IV device impacted demand for the new Inspire V, leading to a need for inventory reduction [4]. - **Training & Onboarding**: Many treatment centers had not completed essential training for the new device, contributing to operational delays [4]. Impact on Business and Stock - The alleged operational failures resulted in a drastic cut to Inspire's 2025 earnings per share (EPS) guidance by over 80%, leading to a stock price drop of $42.04 per share, equating to a 32.4% decline in value [4]. Investigation Focus - Hagens Berman's investigation emphasizes the concealment of critical issues, particularly the Medicare claims software failure and the inventory glut of the prior device, suggesting that management prioritized a narrative of seamless transition over operational reality [5]. Legal Options for Investors - Investors who purchased INSP securities during the class period may have legal options and are encouraged to contact Hagens Berman for further information [5].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [4]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and necessitating an inventory "burn down" [4]. - Many treatment centers had not completed essential training for the new device, contributing to the launch's failure [4]. - As a result of these issues, Inspire Medical slashed its 2025 EPS guidance by over 80%, leading to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman to discuss their legal rights before the January 5, 2026, Lead Plaintiff Deadline [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational failures and is inviting investors to share information that may assist in the investigation [5].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors regarding operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [2][3]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, preventing implanting centers from billing for procedures [3]. - An excess inventory of the older Inspire IV device created a channel glut, negatively impacting demand for the new Inspire V product and leading to a significant reduction in 2025 earnings per share (EPS) guidance by over 80% [3]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [3]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [4].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Lawsuit Details - The lawsuit claims that Inspire Medical and its executives assured investors of the company's "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][4]. - The class period for the lawsuit includes investors who purchased INSP securities between August 6, 2024, and August 4, 2025 [2]. - The lead plaintiff deadline for the lawsuit is January 5, 2026, urging affected investors to contact the law firm Hagens Berman [3]. Group 2: Allegations of Concealment - Allegations include failures in Medicare claims processing software that delayed the rollout of the Inspire V device, impacting revenue generation [4]. - An excess inventory of the older Inspire IV device created a demand issue for the new Inspire V, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 3: Investigation Focus - Hagens Berman's investigation emphasizes the concealment of critical operational issues, particularly the Medicare claims software failure and the inventory surplus of the Inspire IV device [5]. - The firm asserts that the stock collapse was due to management prioritizing a narrative of a seamless transition over the actual operational challenges [5].

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Inspire Medical Systems, Inc. due to allegations of false and misleading statements regarding the launch of its Inspire V device, which has led to significant financial losses for investors [2][4]. Company Overview - Inspire Medical Systems, Inc. is a publicly traded company on the NYSE under the ticker INSP [2]. - The company has faced serious challenges in launching its new Inspire V device, including logistical issues and weak market demand [5][6]. Legal Proceedings - A federal securities class action has been filed against Inspire Medical, with a deadline of January 5, 2026, for investors to seek the role of lead plaintiff [2][7]. - The lead plaintiff is defined as the investor with the largest financial interest who can adequately represent the class [7]. Financial Impact - On August 4, 2025, Inspire Medical announced significant setbacks in the launch of the Inspire V device, leading to a more than 80% cut in its 2025 earnings guidance [5][6]. - Following the announcement, Inspire's stock price plummeted over 32%, from $129.95 per share to $87.91 per share, resulting in a loss of approximately $1.2 billion in market capitalization [6]. Issues with Product Launch - The company reported that the rollout of the Inspire V device was delayed due to treatment centers not completing necessary training and onboarding [5]. - Billing and reimbursement challenges were also highlighted, as Medicare's approval of a CPT code for Inspire V did not coincide with the necessary software updates for claims processing [5]. Call for Information - Faruqi & Faruqi encourages anyone with information regarding Inspire Medical's conduct, including whistleblowers and former employees, to come forward [8].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors regarding operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][2]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [2][3]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, causing a bottleneck in revenue generation [3]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [3]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [3]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the January 5, 2026, Lead Plaintiff Deadline to discuss their legal rights [2][4]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [4].

Core Insights - Inspire Medical Systems faced significant setbacks in the launch of its new Inspire V device, revealing that the rollout was delayed due to incomplete training and onboarding at treatment centers [3] - The company also encountered billing and reimbursement challenges, as necessary software updates for claims processing were not implemented until July 1, affecting the ability of implanting centers to bill for procedures [3][4] - Inspire reported weak demand and excess inventory for the Inspire V, leading to a drastic cut in its 2025 earnings guidance by over 80% [4] Financial Impact - Following the announcement of these issues, Inspire's stock price plummeted by more than 32%, dropping from $129.95 per share on August 4, 2025, to $87.91 per share on August 5, 2025, resulting in a loss of approximately $1.2 billion in market capitalization [4] Legal Proceedings - A class action lawsuit has been initiated against Inspire Medical Systems, alleging that the company and its executives made false and misleading statements regarding the market demand for Inspire V and the steps taken for its launch [2][5] - The lead plaintiff in the lawsuit is the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [5]

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which was later revealed to be false due to undisclosed operational issues [3][5]. - Key operational failures included delays in Medicare claims processing software updates, which did not take effect until July 1, 2025, causing a bottleneck in revenue generation [4]. - An excess inventory of the older Inspire IV device negatively impacted demand for the new Inspire V product, leading to a significant cut in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed the necessary training and onboarding for the new device, contributing to a 32.4% decline in stock value, equating to a drop of $42.04 per share [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026 [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that management prioritized a narrative of seamless transition over actual operational realities [5]. - Whistleblowers with non-public information regarding Inspire are encouraged to assist in the investigation, with potential rewards of up to 30% of any successful recovery made by the SEC [6].

Core Viewpoint - A securities class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) for allegedly misleading investors about operational failures related to the launch of its Inspire V device for obstructive sleep apnea [1][3]. Group 1: Allegations and Impact - The lawsuit claims that Inspire Medical assured investors of its "operational readiness" for the Inspire V launch, which concealed significant operational failures that ultimately led to a drastic cut in guidance and a stock price crash [3][5]. - Key undisclosed operational issues include: - Medicare claims software updates were not effective until July 1, 2025, delaying the rollout and revenue generation [4]. - An excess inventory of the older Inspire IV device impacted demand for the new Inspire V, leading to a significant reduction in 2025 earnings per share (EPS) guidance by over 80% [4]. - Many treatment centers had not completed necessary training and onboarding for the new device, contributing to a $42.04 per share drop and a 32.4% decline in stock value [4]. Group 2: Legal Actions and Investor Guidance - Investors who purchased Inspire Medical securities between August 6, 2024, and August 4, 2025, are encouraged to contact Hagens Berman before the Lead Plaintiff Deadline of January 5, 2026, to discuss their legal rights [2][3]. - Hagens Berman is focusing on the alleged concealment of critical operational issues, emphasizing that the stock collapse was due to management prioritizing a narrative over operational reality [5].